Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain

References

• BandelowBZoharJHollanderEKasperSMöllerHJWFSBP task force on treatment guidelines for anxiety obsessive-compulsive post-traumatic stress disordersWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revisionWorld J Biol Psychiatry20094248312
   Google Scholar
• JuddLLKesslerRCPaulusMPZellerPVWittchenHUKunovacJLComorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS)Acta Psychiatr Scand Suppl19983936119777041
   PubMedGoogle Scholar
• BallengerJCDavidsonJRLecrubierYConsensus statement of generalized anxiety disorder from the international consensus group on depression and anxietyJ Clin Psychiatry200162 Suppl 11535811414552
   PubMed Web of Science ®Google Scholar
• WittchenHUKesslerRCBeesdoKKrausePHoflerMHoyerJGeneralized anxiety and depression in primary care: prevalence, recognition, and managementJ Clin Psychiatry200263 Suppl 8243412044105
   PubMed Web of Science ®Google Scholar
• AlonsoJAngermeyerMCBernertSPrevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) projectActa Psychiatr Scand Suppl2004Suppl 420212715128384
   PubMedGoogle Scholar
• KesslerRCWittchenHUPatterns and correlates of generalized anxiety disorder in community samplesJ Clin Psychiatry200263 Suppl 841012044107
   PubMed Web of Science ®Google Scholar
• Chocron BentataLVilalta FranchJLegazpi RodriguezIAuquerKFranchLPrevalence of psychopathology at a primary care centerAten Primaria199516586590 Spanish8555389
   PubMedGoogle Scholar
• CaballeroLBobesJVilardagaIRejasJClinical prevalence and reason for visit of patients with generalized anxiety disorder seen in the psychiatry out-patient clinics in Spain. Results of the LIGANDO studyActas Esp Psiquiatr2009371720 Spanish18815907
   PubMed Web of Science ®Google Scholar
• KesslerRCBerglundPDemlerOJinRMerikangasKRWaltersEELifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey ReplicationArch Gen Psychiatry20056259360215939837
   PubMed Web of Science ®Google Scholar
• LiebRBeckerEAltamuraCThe epidemiology of generalized anxiety disorder in EuropeEur Neuropsychopharmacol20051544545215951160
   PubMed Web of Science ®Google Scholar
• KatzmanMACurrent considerations in the treatment of generalized anxiety disorderCNS Drugs20092310312019173371
   PubMed Web of Science ®Google Scholar
• Andlin-SobockiPWittchenHUCost of anxiety disorders in EuropeEur J Neurol200512 Suppl 1394415877777
   PubMed Web of Science ®Google Scholar
• McLaughlinTPKhandkerRKKruzikasDTTummalaROverlap of anxiety and depression in a managed care population: prevalence and association with resource utilizationJ Clin Psychiatry2006671187119316965195
   PubMed Web of Science ®Google Scholar
• WittchenHUGeneralized anxiety disorder: prevalence, burden, and cost to societyDepress Anxiety20021616217112497648
   PubMed Web of Science ®Google Scholar
• PollackMHRefractory generalized anxiety disorderJ Clin Psychiatry200970 Suppl 2323819371505
   PubMed Web of Science ®Google Scholar
• DavidsonJRFirst-line pharmacotherapy approaches for generalized anxiety disorderJ Clin Psychiatry200970 Suppl 2253119371504
   PubMed Web of Science ®Google Scholar
• RickelsKDowningRSchweizerEHassmanHAntidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepamArch Gen Psychiatry1993508848958215814
   PubMed Web of Science ®Google Scholar
• GeeNSBrownJPDissanayakeVUOffordJThurlowRWoodruffGNThe novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channelJ Biol Chem1996271576857768621444
   PubMed Web of Science ®Google Scholar
• DooleyDJDonovanCMPugsleyTAStimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalinJ Pharmacol Exp Ther20002951086109311082444
   PubMed Web of Science ®Google Scholar
• ManeufYPHughesJMcKnightATGabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudal trigeminal nucleus slicesPain2001939196
   Web of Science ®Google Scholar
• FinkKDooleyDJMederWPInhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortexNeuropharmacology20024222923611804619
   PubMed Web of Science ®Google Scholar
• KonnopkaALeichsenringFLeibingEKönigHHCost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic reviewJ Affect Disord2009114143118768222
   PubMed Web of Science ®Google Scholar
• Vera-LlonchMDukesERejasJSofryginOMychaskiwMOsterGCost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspectiveEur J Health Econ201011354419506926
   PubMed Web of Science ®Google Scholar
• ÁlvarezECarrascoJLOlivaresJMBroadening of generalized anxiety disorders definition does not affect the response to therapy: findings from the ADAN studyEur Psychiatry201025Suppl 1 Abstract PW01-50
   Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text RevisionWashington, DCAmerican Psychiatric Association2000
   Google Scholar
• HamiltonMThe assessment of anxiety states by ratingBr J Med Psychol195932505513638508
   PubMed Web of Science ®Google Scholar
• LoboAChamorroLLuqueADal-RéRBadíaXBaróEValidación de las versiones en espanol de la Montgomery-Asberg Depression Scale y la Hamilton Anxiety Rating Scale para la evaluación de la depresión y de la ansiedadMed Clin (Barc)2002118493499 Spanish11975886
   PubMed Web of Science ®Google Scholar
• GuyWECDEU Assessment Manual for Psychopharmacology RevisedRockville, MDUS Department of Health Education, and Welfare, Psychopharmacology Research Branch1976
   Google Scholar
• EuroQoL GroupEuroQoL – a new facility for the measurement of health-related quality of lifeHealth Policy19901619920810109801
   PubMed Web of Science ®Google Scholar
• BadíaXRosetMMontserratSHerdmanMSeguraAThe Spanish version of EuroQoL: a description and its applications. European Quality of Life scaleMed Clin (Barc)1999112Suppl 17985 Spanish
   PubMed Web of Science ®Google Scholar
• SacristánJAOlivaJDel LlanoJPrietoLPintoJLQué es una tecnología sanitaria eficiente en Espana?Gac Sanit20024334343 Spanish
   Google Scholar
• Catálogo del Consejo General de Colegios Farmacéuticos de Espana, BOT base de datos del medicamento 2008.
   Google Scholar
• Oblikue2008eSALUD. Base de datos de costes sanitariosSocialSCdEeEdlSyPSoikosBarcelona
   Google Scholar
• INE [http://www.ine.es]Spain 2008Accessed Aug 2008
   Google Scholar
• RevickiDBrandenburgMMatzaLSRelationship between anxiety severity and health utility index scores in generalized anxiety disorderPresented at the Collegium of Internationale Neuro-PsycharmacologicumChicago, ILJuly 9–13, 2006
   Google Scholar
• MorlockRShahHFeltnerDBrandenburgNMatzaLSRevickiDEstimation of health-state utilities for patients with generalized anxiety disorderPresented at the Collegium of Internationale Neuro-PsycharmacologicumChicago, ILJuly 9–132006
   Google Scholar
• BastidaJLOlivaJAntonanzasFA proposed guideline for economic evaluation of health technologiesGac Sanit201024154170 Spanish19959258
   PubMed Web of Science ®Google Scholar
• GaoKSheehanDVCalabreseJRAtypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disordersExpert Rev Neurother200991147115819673604
   PubMed Web of Science ®Google Scholar
• HeuzenröederLDonnellyMHabyMMCost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorderPsychiatry200438602612
   Google Scholar
• IssakidisCSandersonKCorryJAndrewsGLapsleyHModelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disordersPsychol. Med200434193514971624
   PubMed Web of Science ®Google Scholar
• GuestJFRussJLenox-SmithACost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalized anxiety disorder in the United KingdomEur J Health Econ2005613614515682285
   PubMedGoogle Scholar
• JørgensenTRSteinDJDespiegelNDrostPBHemelsMEBaldwinDSCost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United KingdomAnn Pharmacother2006401752175816985090
   PubMed Web of Science ®Google Scholar
• BaldinettiFBandelowBKasperSEfficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trialInt Clin Psychopharmacol200924879621456104
   PubMed Web of Science ®Google Scholar
• WeinsteinMCO’BrienBHornbergerJISPOR Task Force on Good Research PracticesPrinciples of good practice for decision analytic modelling in health care evaluation: report of the ISPOR Task Force on good research practices – modeling studiesValue Health2003691712535234
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical ExcellenceGuide to the Methods of Technology AppraisalLondon, UKNational Institute for Clinical Excellence2004
   Google Scholar
• PollackMHOttoMWRoy-ByrnePPNovel treatment approaches for refractory anxiety disordersDepress Anxiety20082546747617437259
   PubMed Web of Science ®Google Scholar
• SimonNMConnorKMLeBeauRTQuetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findingsPsychopharmacology (Berl)200819767568118246327
   PubMed Web of Science ®Google Scholar
• PollackMHSimonNMZaltaAKOlanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled studyBiol Psychiatry20065921121516139813
   PubMed Web of Science ®Google Scholar